3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 20...(c recombinant human thrombopoietin...)
Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results
Date:3/11/2009
c recombinant human thrombopoietin ("TPO") products, continued their rapid uptake trend and are increasingly adopted as the standard of care for Chemo Induced Thrombocytopenia. TPIAO net revenue increased 39.7% year-over-year in the fourth quarter of 2008 to RMB16.4 million (US$2.4 million), and increased 56.9% in 2008 to RMB67.6 million (US$9.9 million). -- 3SBio completed all three Phase III programs on schedule, and submitted them for SFDA approval: -- In September 2008, the Company filed for approval of a 36,000 IU dosage formulation of EPIAO for the treatment of anemia associated with chemotherapy in cancer patients. If approved, 36,000 IU dosage formulation of EPIAO will further enhance the Company's effort to penetrate Oncology market given the convenience of a weekly injection. -- In November 2008, the Company filed for approval of NuLeusin for the treatment of late stage metastatic renal cell carcinoma, and if approved this is expected to be the only treatment of this kind available in China. NuLeusin, 3SBio's second-generation IL-2, is a genetically modified form of IL-2, possessing improved biochemical properties over naturally occurring IL-2. -- In December 2008, the Company filed for approval of a TPIAO label extension for the treatment of idiopathic thrombocytopenic purpura (ITP) in China, representing the first of a series of indications that the Company plans to pursue to build and grow TPIAO brand. -- 3SBio demonstrated its business development capabilities through a strategic partnership with AMAG Pharmaceutical, to develop and commercialize Ferumoxytol, a new generation of IV Iron therapy, in China. 3SBio plans to initiate China SFDA registration trials in 2009, further enhancing the Company's l
'/>"/>
| SOURCE 3SBio Inc. Copyright©2009 PR Newswire. All rights reserved |
Related biology technology :
1. 3SBio Inc. Receives Official Recognition as a High-Tech Enterprise
2. 3SBio Inc. to Report 2008 Fourth Quarter and Full Year Earnings on March 11, 2009
3. 3SBio Inc. Appoints Mr. Bo Tan as Chief Financial Officer
4. 3SBio Inc. to Present at the Piper Jaffray 20th Annual Health Care Conference
5. 3SBio Inc. Announces Third Quarter 2008 Results
6. 3SBio Inc. Files for SFDA Approval of NuLeusin
7. 3SBio Inc. Announces Preliminary Third Quarter 2008 Results
8. 3SBio Inc. Schedules 2008 Third Quarter Earnings Release on Monday, November 10, 2008
9. 3SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO
10. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
11. 3SBio Inc. Announces Results of Annual General Meeting
Post Your Comments:
(Date:11/30/2009)... The Michael J. Fox Fou...unced $1.5 million in total awards to six research...fying therapies for Parkinson,s disease. The fundi... Discovery for Parkinson,s Disease program, made ...SE: ELN ), a neuroscience-based biotechnology co...
(Date:11/30/2009)...China and LOS ANGELES, Nov. 30 /PRNewswire-Asia-Fi...TC Bulletin Board: CYXN; ,China Yongxin,Pharmaceut...distributor and,retailer of pharmaceuticals in Nor...preparation for distribution of medicines on the E...ent recently formalized the nation,s Essential Dru...
(Date:11/30/2009)...HAGEN, Nov. 30 Exiqon A/S (NASDAQ ...rvard Medical School ICCB-Longwood Screening Facil...eening Center of Excellence. ICCB-L supports inve...d hospitals and institutions, for high-throughput ..., MicroRNAs are a novel class of small, non-codi...
(Date:11/28/2009)...Vanuatu National Advisory Committee on Climate Cha...ion (SNC) Project in collaboration with the Vanuat...New Zealand have generated preliminary climate cha...background for the country’s SNC reporting t...te Change (UNFCCC). , Po...
Breaking Biology Technology:The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 2The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 3China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 2China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 3Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 2Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 3Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 2Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 3Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 4[0] The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments[0] China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List[0] Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence[0] Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM
...erday from a week,s trip to Sao Paulo, Brazil, whe...Management-Latin America course, a group of execut...er, Abbott, Hospira, Grainger, Motorola, AT&T) to ...ne huge megapolis! Having recently returned from w...e world, Delhi (15.0 million people) and Mumbai (1...
...moTherapy has announced the opening of a multi-di...r at its Madison headquarters. , ,The company, whi...ic offering of stock, said engineers, physicists, ...als who will receive on-site, interactive training...d conditions at global Hi-Art system sites. , ,Tom...
...e delivered a keynote address at the recent Digit...John Wade, the chair-elect of the Healthcare Info...mingly contradictory stance by the Internal Reven...on technology. , ,Wade noted the IRS had threatene...hcare practices that adopt electronic medical reco...
Other Biology Technology:Brazilian bio-industry should impress American investors 2Brazilian bio-industry should impress American investors 3Brazilian bio-industry should impress American investors 4Brazilian bio-industry should impress American investors 5Brazilian bio-industry should impress American investors 6IRS ruling could speed healthcare technology adoption 2IRS ruling could speed healthcare technology adoption 3IRS ruling could speed healthcare technology adoption 4IRS ruling could speed healthcare technology adoption 5(Date:11/30/2009)...l temperatures continue to rise scientists are pre... how species respond and adapt. In a paper publish...cisco Rodriguez-Trelles and Dr Miguel Rodriguez as...warming of approximately 0.6˚C has already af...ge facing ecologists and evolutionary biologists i...
(Date:11/30/2009)... , VILNIUS, Lithuania, Nov. 30 /PRNewswire/ ...m ), a provider of high-precision biometric identi...es in the company,s core product line: VeriLook ...gnition and MegaMatcher 3.1 SDK for large-scale ...cation systems (AFIS). Expanded capabilities in Ve...
(Date:11/26/2009)... carried out in eight European countries has shown...s disease pandemic could have a significant role i...ng in the open access journal BMC Infectious Dise...ol days and weekends/holidays, finding that they w...from Hasselt and Antwerp University, Belgium, led ...
Breaking Biology News(10 mins):How can scientists measure evolutionary responses to climate change? 2New VeriLook 4.0 for Biometric Facial Recognition and MegaMatcher 3.1 for Multi-biometric Applications Are Now Available 2New VeriLook 4.0 for Biometric Facial Recognition and MegaMatcher 3.1 for Multi-biometric Applications Are Now Available 3School closure could reduce swine flu transmission by 21 percent 2Childrens Author Tells Americas Youth To Dream Big By Inspiring The Hero In Every Child 57182 1Childrens Author Tells Americas Youth To Dream Big By Inspiring The Hero In Every Child 57182 2Childrens Author Tells Americas Youth To Dream Big By Inspiring The Hero In Every Child 57182 3Accuray Announces Additions to Board of Directors 57179 1Accuray Announces Additions to Board of Directors 57179 2Accuray Announces Additions to Board of Directors 57179 3Ganeden Biotech Introduces the First Probiotic Thin Strip 14053 1Ganeden Biotech Introduces the First Probiotic Thin Strip 14053 2Ganeden Biotech Introduces the First Probiotic Thin Strip 14053 3...mia might be to knock out a specific protein that ...s. , The findings suggest that a drug that can bl... effective therapy. , But such a drug used in ... offer an effective one-two punch against drug-res... and acute lymphoblastic leukemia (ALL). The two f...
...ganda who self-paid for their antiretroviral medic...e to either financial demands or supply logistical...o the development of resistance to antiretroviral ...m led by researchers at the Infectious Diseases In...are reported in the April 22, 2007 issue of the jo...
... bacteria commonly found in US meat and poultry re...e plague bacillus Yersinia pestis, gene sequence r...of the antibiotics used against plague has been fo... Madagascar. But because the same ability is prese...f livestock, antibiotic resistance could potential...
Other Biology News:Knocking out survival protein could aid leukemia treatment 2Resistance to anti-HIV drugs in Uganda developed due to drug supply problems 2Will the plague pathogen become resistant to antibiotics? 2Yeast Extract Solution from Invitrogen
(Miller's LB Broth Base) Luria Broth Base powder from Invitrogen
Bsg I from New England Biolabs
GIBCO Geneticin Selective Antibiotic liquid from Invitrogen
Biology Products:| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |